Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
M Lia Palomba, Stephen J Schuster, Reem Karmali, Alan P Skarbnik, Jeremy Abramson, Kirit Ardeshna, Peter Borchmann, Brian T Hill, Alejandro Martin García-Sancho, Gianpaolo Marcacci, Aaron P. Rapoport, Guillaume Cartron, Isabelle Fleury, Koji Izutsu, Manali Kamdar, Stephan Mielke, Anna Maria Barbui, Juan Luis Reguera Ortega, Loretta J Nastoupil, Sairah Ahmed, Merav Bar, Lizbeth Diaz, Ulrika Furustrand, Victoria Diab, Min Vedal, Ariel Avilion, Jinender Kumar, Rina Nishii, Silvia Colicino, Franck Morschhauser
Topics & Concepts
MedicineRefractory (planetary science)Internal medicinePhases of clinical researchOncologyGastroenterologyPhase (matter)LymphomaSurgeryPrimary (astronomy)Clinical trialSubgroup analysisIntention-to-treat analysisNuclear medicineLymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders research